These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
207 related items for PubMed ID: 26349547
21. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Künstlinger H, Huss S, Merkelbach-Bruse S, Binot E, Kleine MA, Loeser H, Mittler J, Hartmann W, Hohenberger P, Reichardt P, Büttner R, Wardelmann E, Schildhaus HU. Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512 [Abstract] [Full Text] [Related]
22. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours. Wang C, Jin MS, Zou YB, Gao JN, Li XB, Peng F, Wang HY, Wu ZD, Wang YP, Duan XM. Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765 [Abstract] [Full Text] [Related]
23. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS, Yook JH, Kim BS, Lee JS. Clin Cancer Res; 2004 May 01; 10(9):3076-81. PubMed ID: 15131046 [Abstract] [Full Text] [Related]
24. KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Braconi C, Bracci R, Bearzi I, Bianchi F, Costagliola A, Catalani R, Mandolesi A, Ranaldi R, Galizia E, Cascinu S, Rossi G, Giustini L, Latini L, Valeri N, Cellerino R. Ann Oncol; 2008 Apr 01; 19(4):706-10. PubMed ID: 18187489 [Abstract] [Full Text] [Related]
25. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. Braggio E, Braggio Dde A, Small IA, Lopes LF, Valadão M, Gouveia ME, Moreira Ados S, Linhares E, Romano S, Bacchi CE, Renault IZ, Guimarães DP, Ferreira CG. Anticancer Res; 2010 Jun 01; 30(6):2407-14. PubMed ID: 20651400 [Abstract] [Full Text] [Related]
26. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors. Jasek K, Buzalkova V, Minarik G, Stanclova A, Szepe P, Plank L, Lasabova Z. Virchows Arch; 2017 Jan 01; 470(1):29-36. PubMed ID: 27864688 [Abstract] [Full Text] [Related]
27. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro J, Maurel J, Calabuig S, Gutierrez A, González de Sande JL, Martínez J, De Juan A, Laínez N, Losa F, Alija V, Escudero P, Casado A, García P, Blanco R, Buesa JM, Spanish Group for Sarcoma Research. J Clin Oncol; 2005 Sep 01; 23(25):6190-8. PubMed ID: 16135486 [Abstract] [Full Text] [Related]
28. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, Gronchi A, Casali PG, Maestro R, Dei Tos AP. Am J Surg Pathol; 2015 Jul 01; 39(7):922-30. PubMed ID: 25970686 [Abstract] [Full Text] [Related]
30. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors]. Tang M, Li DQ. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan 01; 11(1):80-3. PubMed ID: 18197502 [Abstract] [Full Text] [Related]
33. C-KIT and PDGFRA zygosity in gastrointestinal stromal tumors: Correlation with tumor site, tumor size, exon, and CD117 immunohistochemistry. Wallander ML, Willmore-Payne C, Layfield LJ. Appl Immunohistochem Mol Morphol; 2011 Jan 01; 19(1):21-7. PubMed ID: 20823768 [Abstract] [Full Text] [Related]
34. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP. J Clin Pathol; 2009 Jul 01; 62(7):613-6. PubMed ID: 19561230 [Abstract] [Full Text] [Related]
35. Correlation between mutational status and survival and second cancer risk assessment in patients with gastrointestinal stromal tumors: a population-based study. Rubió-Casadevall J, Borràs JL, Carmona-García MC, Ameijide A, Gonzalez-Vidal A, Ortiz MR, Bosch R, Riu F, Parada D, Martí E, Miró J, Sirvent JJ, Galceran J, Marcos-Gragera R. World J Surg Oncol; 2015 Feb 13; 13():47. PubMed ID: 25885906 [Abstract] [Full Text] [Related]
37. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis. Zong L, Chen P. World J Surg Oncol; 2014 Mar 28; 12():71. PubMed ID: 24674052 [Abstract] [Full Text] [Related]
38. SKP2 high expression, KIT exon 11 deletions, and gastrointestinal bleeding as predictors of poor prognosis in primary gastrointestinal stromal tumors. Lv A, Li Z, Tian X, Guan X, Zhao M, Dong B, Hao C. PLoS One; 2013 Mar 28; 8(5):e62951. PubMed ID: 23690967 [Abstract] [Full Text] [Related]
39. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU. Virchows Arch; 2007 Oct 28; 451(4):743-9. PubMed ID: 17701051 [Abstract] [Full Text] [Related]